Viz.ai and Cortechs.ai are collaborating to integrate Cortechs.ai's NeuroQuant MS quantitative MRI analysis suite into the Viz.ai care coordination platform.
The integration will enable clinicians to access quantitative MRI analysis for multiple sclerosis (MS) directly within Viz.ai's care coordination workflow, according to the companies. Viz.ai said the partnership marks its expansion into neurodegenerative disease, growing its Viz Neuro Suite beyond its existing neurological offerings. The company said additional partnership and product announcements focused on neurodegenerative diseases are expected in the near future.
Viz.ai's platform is currently deployed at nearly 2,000 U.S. hospitals, according to the company.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
